SecBot SecBot
8-K ·Filed May 12, 2026

ARVN

ARVINAS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001628280-26-033874
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

This deal provides Arvinas with near-term cash ($42.5M upfront) and a path to monetize VEPPANU without bearing full commercialization costs. The NCCN guideline inclusion days before the deal strengthens the asset's value. Watch for HSR clearance timeline and any Rigel execution updates. The deal allows Arvinas to focus on its early-stage pipeline (ARV-102, ARV-806, ARV-393, ARV-027).

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.57
T+0 close · May 12, 2026 · via day close
Latest settled
−9.30%
T+60 · $8.68
Vs SPY
−13.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $9.57entry
  2. T+1 · 6mo ago +3.13%α +2.56% · $9.87
  3. T+5 · 6mo ago −8.26%α −8.33% · $8.78
  4. T+20 · 5mo ago −27.06%α −25.34% · $6.98
  5. T+60 · 3mo ago −9.30%α −13.68% · $8.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC for ER+/HER2- breast cancer. Arvinas and Pfizer will receive $85 million in upfront and near-term payments, split evenly, with up to $320 million in milestones and tiered mid-teens to mid-20s royalties. Rigel takes over U.S. commercialization and owns global rights with sublicensing ability.

Key Financial Metrics

Deal Value
$85.0M
Deal Type
license

Key Facts

  • Arvinas and Pfizer entered a license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC for ER+/HER2- advanced breast cancer.
  • Rigel will pay $70 million upfront and $15 million upon completion of select development/manufacturing transition activities, split evenly between Arvinas and Pfizer.
  • Arvinas and Pfizer are eligible for up to $320 million in development, regulatory, and commercial milestone payments plus tiered royalties in the mid-teens to mid-20s on worldwide net sales.
  • Rigel will contribute up to $40 million toward ongoing development activities.
  • Closing is subject to HSR antitrust waiting period expiration or termination.
  • VEPPANU was added to NCCN Guidelines as a Category 2A treatment option on May 8, 2026.

Financial Impact

Arvinas receives $42.5 million upfront (half of $85M) with potential for $160 million in milestones and tiered royalties. Deal replaces unearned future payments from Pfizer under the 2021 collaboration agreement.

revenuecash_runway

Risk Factors

  • HSR clearance may delay or block closing.
  • Rigel's commercial execution risk for VEPPANU in a competitive breast cancer market.
  • Milestone and royalty payments are contingent on future development and commercial success.
  • Arvinas' share of payments is split 50/50 with Pfizer, reducing per-company upside.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-033874
Document: arvn_veppanuxoutlicensex.htm0001628280-26-033874
Document: 0001628280-26-033874-index-headers.html0001628280-26-033874
Document: 0001628280-26-033874-index.html0001628280-26-033874
Document: 0001628280-26-033874.txt0001628280-26-033874

Track record

21 reports on ARVN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Viewing Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026